Precigen
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies.
Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cell therapies.
Precigen, a biopharmaceutical company listed on Nasdaq (PGEN) is focused on advancing the next generation of gene and cell therapies. Founded in 1998 and headquartered in the United States, Precigen is dedicated to addressing urgent and intractable diseases in the areas of immuno-oncology, autoimmune disorders, and infectious diseases using precision technology.
The company operates as an innovation engine, progressing a preclinical and clinical pipeline of unique therapies towards clinical proof-of-concept and commercialization. With a focus on affordability, Precigen's technologies enable the development of innovative solutions for biotherapeutics in a controlled manner.
Precigen recently received a $75.00M Post-IPO Equity investment on 24 January 2023, signifying investor confidence in the company's potential to make significant advancements in the biotechnology industry.
Overall, Precigen's commitment to advancing medicine with precision and its strong focus on developing groundbreaking therapies positions it as an attractive prospect for venture capitalists seeking exposure to the evolving biopharmaceutical landscape.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $75.00M | - | 24 Jan 2023 | |
| Post-IPO Equity | $129.40M | - | 22 Jan 2021 | |
| Post-IPO Equity | $35.00M | - | 03 Feb 2020 | |
| Post-IPO Equity | $57.50M | - | 28 Jan 2015 | |
| Series F | $150.00M | 2 | Third Security, Randal J. Kirk | 02 May 2013 |
No recent news or press coverage available for Precigen.
We care about your data, and we'd love to use cookies make your experience better.
